Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 61.06m |
Free float | 60.97m |
P/E (TTM) | 34.23 |
Market cap | 28.52bn EUR |
EPS (TTM) | 13.65 EUR |
--
More ▼
Announcements
- argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
- argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
- argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
- argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
- argenx Announces Results of Annual General Meeting of Shareholders
- argenx Reports First Quarter 2025 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2025 Health Care Conference
- argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
- argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- argenx Announces Annual General Meeting of Shareholders on May 27, 2025
More ▼